{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,28]],"date-time":"2026-06-28T16:45:25Z","timestamp":1782665125235,"version":"3.54.5"},"reference-count":62,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,6,1]],"date-time":"2026-06-01T00:00:00Z","timestamp":1780272000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,6,1]],"date-time":"2026-06-01T00:00:00Z","timestamp":1780272000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,4,20]],"date-time":"2026-04-20T00:00:00Z","timestamp":1776643200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100022011","name":"CRUK","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100022011","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100014653","name":"BRC","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100014653","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","lungcancerjournal.info","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Lung Cancer"],"published-print":{"date-parts":[[2026,6]]},"DOI":"10.1016\/j.lungcan.2026.109411","type":"journal-article","created":{"date-parts":[[2026,4,15]],"date-time":"2026-04-15T06:09:47Z","timestamp":1776233387000},"page":"109411","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"special_numbering":"C","title":["Navigating controversies in stage III NSCLC: a multidisciplinary case discussion on evolving treatment paradigms"],"prefix":"10.1016","volume":"216","author":[{"ORCID":"https:\/\/orcid.org\/0009-0007-6905-6896","authenticated-orcid":false,"given":"Ashley","family":"Horne","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5364-2491","authenticated-orcid":false,"given":"Igor","family":"Gomez-Randulfe","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Amy","family":"Ford","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0001-7809-2430","authenticated-orcid":false,"given":"Richard","family":"Milton","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Petra","family":"Jankowska","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6904-1327","authenticated-orcid":false,"given":"Emma","family":"O\u2019Dowd","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9168-0387","authenticated-orcid":false,"given":"Alastair","family":"Greystoke","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5617-9781","authenticated-orcid":false,"given":"Corinne","family":"Faivre-Finn","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"1","key":"10.1016\/j.lungcan.2026.109411_b0005","doi-asserted-by":"crossref","DOI":"10.1186\/s12890-025-03715-9","article-title":"Real-world treatment patterns and outcomes for patients with non-metastatic non-small cell lung cancer: retrospective analyses in Canada, England, and Germany","volume":"25","author":"Greystoke","year":"2025","journal-title":"BMC Pulm. Med."},{"key":"10.1016\/j.lungcan.2026.109411_b0010","doi-asserted-by":"crossref","unstructured":"Zer A, Ahn MJ, Barlesi F, Bubendorf L, Ruysscher DD, Garrido P, et al. Early and locally advanced non-small-cell lung cancer: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up\u2606. Annals of Oncology. 2025 Aug 28;0(0). doi:10.1016\/j.annonc.2025.08.003 PubMed PMID: 40885528.","DOI":"10.1016\/j.annonc.2025.08.003"},{"issue":"199","key":"10.1016\/j.lungcan.2026.109411_b0015","article-title":"An international and multidisciplinary EORTC survey on resectability of stage III non-small cell lung cancer","volume":"1","author":"Houda","year":"2025","journal-title":"Lung Cancer"},{"key":"10.1016\/j.lungcan.2026.109411_b0020","doi-asserted-by":"crossref","DOI":"10.1016\/j.lungcan.2025.108798","article-title":"Definition of resectable stage III non-small cell lung cancer (NSCLC) for inclusion in clinical trials: a clinical case review by a pan-European multidisciplinary expert panel led by the EORTC Lung Cancer Group","volume":"209","author":"Brand\u00e3o","year":"2025","journal-title":"Lung Cancer"},{"issue":"12","key":"10.1016\/j.lungcan.2026.109411_b0025","doi-asserted-by":"crossref","first-page":"1301","DOI":"10.1200\/JCO.21.01308","article-title":"Five-Year Survival Outcomes from the PACIFIC Trial: Durvalumab after Chemoradiotherapy in Stage III Non\u2013Small-Cell Lung Cancer","volume":"40","author":"Spigel","year":"2022","journal-title":"JCO"},{"issue":"1","key":"10.1016\/j.lungcan.2026.109411_b0030","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1038\/s41571-025-01080-4","article-title":"Unresectable stage III non-small-cell lung cancer: state of the art and challenges","volume":"23","author":"Remon","year":"2026","journal-title":"Nat. Rev. Clin. Oncol."},{"key":"10.1016\/j.lungcan.2026.109411_b0035","doi-asserted-by":"crossref","unstructured":"Detterbeck FC, Boffa DJ, Kim AW, Tanoue LT. The Eighth Edition Lung Cancer Stage Classification. Chest. 2017 Jan;151(1):193\u2013203. doi:10.1016\/j.chest.2016.10.010.","DOI":"10.1016\/j.chest.2016.10.010"},{"key":"10.1016\/j.lungcan.2026.109411_b0040","doi-asserted-by":"crossref","unstructured":"Detterbeck FC, Woodard GA, Bader AS, Dacic S, Grant MJ, Park HS, et al. The Proposed Ninth Edition TNM Classification of Lung Cancer. CHEST. 2024 Oct;166(4):882\u201395. doi:10.1016\/j.chest.2024.05.026.","DOI":"10.1016\/j.chest.2024.05.026"},{"issue":"3","key":"10.1016\/j.lungcan.2026.109411_b0045","doi-asserted-by":"crossref","first-page":"S149","DOI":"10.1016\/S1556-0864(25)00428-9","article-title":"235P: a stage III, non-small cell lung cancer (NSCLC) multidisciplinary meeting (MDT) to increase access to concurrent chemo-radiation in a Northern UK cancer centre","volume":"20","author":"Pickles","year":"2025","journal-title":"J. Thorac. Oncol."},{"issue":"21","key":"10.1016\/j.lungcan.2026.109411_b0050","doi-asserted-by":"crossref","first-page":"1973","DOI":"10.1056\/NEJMoa2202170","article-title":"Neoadjuvant Nivolumab plus Chemotherapy in Resectable Lung Cancer","volume":"386","author":"Forde","year":"2022","journal-title":"N. Engl. J. Med."},{"issue":"5","key":"10.1016\/j.lungcan.2026.109411_b0055","doi-asserted-by":"crossref","first-page":"1327","DOI":"10.1016\/j.jtcvs.2022.01.019","article-title":"Surgical outcomes after neoadjuvant nivolumab or nivolumab with ipilimumab in patients with non\u2013small cell lung cancer","volume":"164","author":"Sepesi","year":"2022","journal-title":"J. Thorac. Cardiovasc. Surg."},{"issue":"6","key":"10.1016\/j.lungcan.2026.109411_b0060","doi-asserted-by":"crossref","first-page":"884","DOI":"10.1111\/resp.12520","article-title":"The effectiveness of lung cancer MDT and the role of respiratory physicians","volume":"20","author":"Prabhakar","year":"2015","journal-title":"Respirology"},{"key":"10.1016\/j.lungcan.2026.109411_b0065","doi-asserted-by":"crossref","unstructured":"H van T, Os H, Ef S, Jh van den B, Aj S, Ra S, et al. Effectiveness of positron emission tomography in the preoperative assessment of patients with suspected non-small-cell lung cancer: the PLUS multicentre randomised trial. Lancet (London, England). 2002 Apr 20;359(9315). doi:10.1016\/s0140-6736(02)08352-6 PubMed PMID: 11978336.","DOI":"10.1016\/S0140-6736(02)08352-6"},{"issue":"1","key":"10.1016\/j.lungcan.2026.109411_b0070","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1016\/j.radonc.2017.02.011","article-title":"Positron emission tomography and computed tomographic imaging (PET\/CT) for dose planning purposes of thoracic radiation with curative intent in lung cancer patients: a systematic review and meta-analysis","volume":"123","author":"Hallqvist","year":"2017","journal-title":"Radiother. Oncol."},{"key":"10.1016\/j.lungcan.2026.109411_b0075","doi-asserted-by":"crossref","first-page":"88","DOI":"10.1016\/j.ejca.2019.04.017","article-title":"Screening for brain metastases in patients with stage III non-small-cell lung cancer, magnetic resonance imaging or computed tomography?","volume":"115","author":"Schoenmaekers","year":"2019","journal-title":"A Prospective Study. Eur J Cancer."},{"key":"10.1016\/j.lungcan.2026.109411_b0080","article-title":"Aug 1","author":"Dunne","year":"2023","journal-title":"Located at: World"},{"issue":"2","key":"10.1016\/j.lungcan.2026.109411_b0085","doi-asserted-by":"crossref","DOI":"10.1183\/13993003.00800-2018","article-title":"Systematic and combined endosonographic staging of lung cancer (SCORE study)","volume":"53","author":"Crombag","year":"2019","journal-title":"Eur. Respir. J."},{"issue":"1","key":"10.1016\/j.lungcan.2026.109411_b0090","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1183\/09031936.00184308","article-title":"ERS\/ESTS clinical guidelines on fitness for radical therapy in lung cancer patients (surgery and chemo-radiotherapy)","volume":"34","author":"Brunelli","year":"2009","journal-title":"Eur. Respir. J."},{"key":"10.1016\/j.lungcan.2026.109411_b0095","doi-asserted-by":"crossref","DOI":"10.1093\/ejcts\/ezad224","article-title":"European Society of Thoracic Surgeons expert consensus recommendations on technical standards of segmentectomy for primary lung cancer","author":"Brunelli","year":"2023","journal-title":"Eur. J. Cardiothorac. Surg."},{"issue":"4","key":"10.1016\/j.lungcan.2026.109411_b0100","doi-asserted-by":"crossref","first-page":"678","DOI":"10.1513\/AnnalsATS.202002-183OC","article-title":"Preoperative Exercise Training to prevent Postoperative Pulmonary Complications in adults Undergoing Major Surgery. a Systematic Review and Meta-analysis with Trial Sequential Analysis","volume":"18","author":"Assouline","year":"2021","journal-title":"Ann. Am. Thorac. Soc."},{"issue":"12","key":"10.1016\/j.lungcan.2026.109411_b0105","doi-asserted-by":"crossref","first-page":"1689","DOI":"10.1001\/jamaoncol.2024.4890","article-title":"Survival Outcomes of an Early intervention smoking Cessation Treatment after a Cancer Diagnosis","volume":"10","author":"Cinciripini","year":"2024","journal-title":"JAMA Oncol."},{"key":"10.1016\/j.lungcan.2026.109411_b0110","unstructured":"Stewart B. E-cigarettes and Cancer: A Qualitative Risk Assessment. Sydney, Australia: Clinical Oncology Society of Australia; 2025."},{"issue":"1","key":"10.1016\/j.lungcan.2026.109411_b0115","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1093\/oncolo\/oyac226","article-title":"Management of Lung Cancer in the Patient with Interstitial Lung Disease","volume":"28","author":"Frank","year":"2023","journal-title":"Oncologist"},{"issue":"4","key":"10.1016\/j.lungcan.2026.109411_b0120","doi-asserted-by":"crossref","first-page":"248","DOI":"10.1097\/MCP.0000000000000975","article-title":"Immunotherapy-related pneumonitis and the synergic impact of thoracic radiation and preexisting interstitial lung disease","volume":"29","author":"Azhar","year":"2023","journal-title":"Curr. Opin. Pulm. Med."},{"issue":"1","key":"10.1016\/j.lungcan.2026.109411_b0125","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1186\/1749-8090-4-41","article-title":"UK pneumonectomy outcome study (UKPOS): a prospective observational study of pneumonectomy outcome","volume":"4","author":"Powell","year":"2009","journal-title":"J. Cardiothorac. Surg."},{"issue":"6","key":"10.1016\/j.lungcan.2026.109411_b0130","doi-asserted-by":"crossref","first-page":"1054","DOI":"10.1093\/icvts\/ivab340","article-title":"Pneumonectomy for primary lung cancer: contemporary outcomes, risk factors and model validation","volume":"34","author":"Brunswicker","year":"2022","journal-title":"Interact. Cardiovasc. Thorac. Surg."},{"key":"10.1016\/j.lungcan.2026.109411_b0135","doi-asserted-by":"crossref","unstructured":"Gonzalez M, Chriqui LE, D\u00e9caluw\u00e9 H, Aigner C, R\u00e9nyi-V\u00e1mos F, Opitz I, et al. Sleeve lobectomy in patients with non-small-cell lung cancer: a report from the European Society of Thoracic Surgery database 2021. Eur J Cardiothorac Surg. 2022 Dec 1;62(6):ezac502. doi:10.1093\/ejcts\/ezac502.","DOI":"10.1093\/ejcts\/ezac502"},{"issue":"6","key":"10.1016\/j.lungcan.2026.109411_b0140","doi-asserted-by":"crossref","first-page":"587","DOI":"10.1016\/j.cllc.2024.06.007","article-title":"MDT-BRIDGE: Neoadjuvant Durvalumab Plus Chemotherapy Followed by either Surgery and Adjuvant Durvalumab or Chemoradiotherapy and consolidation Durvalumab in Resectable or Borderline-resectable Stage IIB-IIIB NSCLC","volume":"25","author":"Reck","year":"2024","journal-title":"Clin. Lung Cancer"},{"issue":"10","key":"10.1016\/j.lungcan.2026.109411_b0145","doi-asserted-by":"crossref","first-page":"5604","DOI":"10.21037\/jtd-21-1007","article-title":"Comparison of surgical difficulty in patients with resectable non-small cell lung cancer under different neoadjuvant treatment modes: a retrospective cohort study","volume":"13","author":"Zhang","year":"2021","journal-title":"J. Thorac. Dis."},{"issue":"21","key":"10.1016\/j.lungcan.2026.109411_b0150","doi-asserted-by":"crossref","first-page":"3552","DOI":"10.1200\/JCO.2007.13.9030","article-title":"Lung adjuvant cisplatin evaluation: a pooled analysis by the LACE Collaborative Group","volume":"26","author":"Pignon","year":"2008","journal-title":"J. Clin. Oncol."},{"issue":"8","key":"10.1016\/j.lungcan.2026.109411_b0155","doi-asserted-by":"crossref","first-page":"741","DOI":"10.1056\/NEJMoa2502931","article-title":"Overall Survival with Neoadjuvant Nivolumab plus Chemotherapy in Lung Cancer","volume":"393","author":"Forde","year":"2025","journal-title":"N. Engl. J. Med."},{"issue":"17","key":"10.1016\/j.lungcan.2026.109411_b0160","doi-asserted-by":"crossref","first-page":"3249","DOI":"10.1200\/JCO.22.02509","article-title":"US Food and Drug Administration Approval Summary: Nivolumab Plus Platinum-Doublet Chemotherapy for the Neoadjuvant Treatment of patients with Resectable Non\u2013Small-Cell Lung Cancer","volume":"41","author":"Akinboro","year":"2023","journal-title":"J. Clin. Oncol."},{"issue":"10459","key":"10.1016\/j.lungcan.2026.109411_b0165","doi-asserted-by":"crossref","first-page":"1240","DOI":"10.1016\/S0140-6736(24)01756-2","article-title":"Neoadjuvant pembrolizumab plus chemotherapy followed by adjuvant pembrolizumab compared with neoadjuvant chemotherapy alone in patients with early-stage non-small-cell lung cancer (KEYNOTE-671): a randomised, double-blind, placebo-controlled, phase 3 trial","volume":"404","author":"Spicer","year":"2024","journal-title":"Lancet"},{"issue":"6","key":"10.1016\/j.lungcan.2026.109411_b0170","doi-asserted-by":"crossref","first-page":"491","DOI":"10.1056\/NEJMoa2302983","article-title":"Perioperative Pembrolizumab for Early-Stage Non\u2013Small-Cell Lung Cancer","volume":"389","author":"Wakelee","year":"2023","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.lungcan.2026.109411_b0175","doi-asserted-by":"crossref","DOI":"10.1016\/j.iotech.2024.101027","article-title":"LBA3 Perioperative pembrolizumab (pembro) plus neoadjuvant chemotherapy (chemo) in early-stage non-small-cell lung cancer (NSCLC): a 4-year update of KEYNOTE-671","volume":"24","author":"Majem","year":"2024","journal-title":"Immuno-Oncology and Technology."},{"issue":"19","key":"10.1016\/j.lungcan.2026.109411_b0180","doi-asserted-by":"crossref","first-page":"1756","DOI":"10.1056\/NEJMoa2311926","article-title":"Perioperative Nivolumab in Resectable Lung Cancer","volume":"390","author":"Cascone","year":"2024","journal-title":"N. Engl. J. Med."},{"issue":"18","key":"10.1016\/j.lungcan.2026.109411_b0185","doi-asserted-by":"crossref","first-page":"1672","DOI":"10.1056\/NEJMoa2304875","article-title":"Perioperative Durvalumab for Resectable Non-Small-Cell Lung Cancer","volume":"389","author":"Heymach","year":"2023","journal-title":"N. Engl. J. Med."},{"issue":"10","key":"10.1016\/j.lungcan.2026.109411_b0190","doi-asserted-by":"crossref","first-page":"S38","DOI":"10.1016\/j.jtho.2024.09.069","article-title":"OA13.03 Perioperative Durvalumab for Resectable NSCLC (R-NSCLC): Updated Outcomes from the phase 3 AEGEAN Trial","volume":"19","author":"Heymach","year":"2024","journal-title":"J. Thorac. Oncol."},{"key":"10.1016\/j.lungcan.2026.109411_b0195","doi-asserted-by":"crossref","unstructured":"Cascone T, Awad MM, Spicer J, He J, Lu S, Tanaka F, et al. Perioperative nivolumab (NIVO) vs placebo (PBO) in patients (pts) with resectable NSCLC: Updated survival and biomarker analyses from CheckMate 77T. JCO. 2025 Jun 10;43(17_suppl). doi:10.1200\/JCO.2025.43.17_suppl.LBA8010.","DOI":"10.1200\/JCO.2025.43.17_suppl.LBA8010"},{"issue":"2","key":"10.1016\/j.lungcan.2026.109411_b0200","doi-asserted-by":"crossref","first-page":"281","DOI":"10.1016\/j.athoracsur.2025.10.016","article-title":"Clinical characteristics and surgical outcomes of patients receiving perioperative pembrolizumab in KEYNOTE-671","volume":"121","author":"Liberman","year":"2026","journal-title":"Ann. Thorac. Surg."},{"issue":"11","key":"10.1016\/j.lungcan.2026.109411_b0205","doi-asserted-by":"crossref","first-page":"1639","DOI":"10.1016\/j.jtho.2025.06.015","article-title":"Surgical Outcomes with Neoadjuvant Durvalumab Plus Chemotherapy Followed by Adjuvant Durvalumab in Resectable NSCLC","volume":"20","author":"Mitsudomi","year":"2025","journal-title":"J. Thorac. Oncol."},{"key":"10.1016\/j.lungcan.2026.109411_b0210","doi-asserted-by":"crossref","unstructured":"Raimann S, Sch\u00e4r S, Hayoz S, Guckenberger M, Finazzi T, Opitz I, et al. Outcomes in Patients With Resectable Stage III NSCLC Who Did Not Have Definitive Surgery After Neoadjuvant Treatment\u2014A Retrospective Analysis of the SAKK Trials 16\/96, 16\/00, 16\/01, 16\/08, and 16\/14: A Brief Report. JTO Clinical and Research Reports. 2025 Jun 1;6(6). doi:10.1016\/j.jtocrr.2025.100834.","DOI":"10.1016\/j.jtocrr.2025.100834"},{"key":"10.1016\/j.lungcan.2026.109411_b0215","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejca.2023.113404","article-title":"Systematic review and meta-analysis of immune checkpoint inhibitors as single agent or in combination with chemotherapy in early-stage non-small cell lung cancer: Impact of clinicopathological factors and indirect comparison between treatment strategies","volume":"195","author":"Nuccio","year":"2023","journal-title":"Eur. J. Cancer"},{"key":"10.1016\/j.lungcan.2026.109411_b0220","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejca.2024.115118","article-title":"Impact of the timing of immunotherapy administration on overall survival for resectable non-small cell lung cancer (iACORN study): a systematic review and meta-analysis of randomised trials","volume":"214","author":"Patel","year":"2025","journal-title":"Eur. J. Cancer"},{"key":"10.1016\/j.lungcan.2026.109411_b0225","unstructured":"ETOP IBCSG Partners Foundation. An International, Multicentre, Open-label Randomised Phase III Trial to Evaluate the Benefit of Adding Adjuvant Durvalumab After Neoadjuvant Chemotherapy Plus Durvalumab in Patients With Stage IIB-IIIB (N2) Resectable NSCLC [Clinical trial registration] [Internet]. clinicaltrials.gov; 2025 Sep [cited 2025 Nov 6]. Clinical trial registration no.: NCT06284317. Available from: https:\/\/clinicaltrials.gov\/study\/NCT06284317."},{"key":"10.1016\/j.lungcan.2026.109411_b0230","unstructured":"Dawar R. A Phase 2 Study of Circulating Tumor DNA to Predict Response to Neoadjuvant Treatment and De-escalation Adjuvant Immunotherapy in Early-Stage NSCLC (DNA-PREDICT) [Clinical trial registration] [Internet]. clinicaltrials.gov; 2025 Jul [cited 2025 Nov 6]. Clinical trial registration no.: NCT06902272. Available from: https:\/\/clinicaltrials.gov\/study\/NCT06902272."},{"issue":"2","key":"10.1016\/j.lungcan.2026.109411_b0235","doi-asserted-by":"crossref","first-page":"137","DOI":"10.1056\/NEJMoa2304594","article-title":"Overall Survival with Osimertinib in Resected EGFR-Mutated NSCLC","volume":"389","author":"Tsuboi","year":"2023","journal-title":"N. Engl. J. Med."},{"issue":"14","key":"10.1016\/j.lungcan.2026.109411_b0240","doi-asserted-by":"crossref","first-page":"1265","DOI":"10.1056\/NEJMoa2310532","article-title":"Alectinib in Resected ALK-Positive Non-Small-Cell Lung Cancer","volume":"390","author":"Wu","year":"2024","journal-title":"N. Engl. J. Med."},{"issue":"2","key":"10.1016\/j.lungcan.2026.109411_b0245","doi-asserted-by":"crossref","first-page":"161","DOI":"10.1093\/annonc\/mdy553","article-title":"Position of a panel of international lung cancer experts on the approval decision for use of durvalumab in stage III non-small-cell lung cancer (NSCLC) by the Committee for Medicinal Products for Human Use (CHMP)","volume":"30","author":"Peters","year":"2019","journal-title":"Ann. Oncol."},{"key":"10.1016\/j.lungcan.2026.109411_b0250","unstructured":"Research C for DE and. FDA approves durvalumab after chemoradiation for unresectable stage III NSCLC. FDA [Internet]. 2024 Sep 8 [cited 2025 Nov 7]. Available from: https:\/\/www.fda.gov\/drugs\/resources-information-approved-drugs\/fda-approves-durvalumab-after-chemoradiation-unresectable-stage-iii-nsclc."},{"key":"10.1016\/j.lungcan.2026.109411_b0255","unstructured":"Imfinzi | European Medicines Agency (EMA) [Internet]. 2018 [cited 2025 Nov 7]. Available from: https:\/\/www.ema.europa.eu\/en\/medicines\/human\/EPAR\/imfinzi."},{"issue":"13","key":"10.1016\/j.lungcan.2026.109411_b0260","doi-asserted-by":"crossref","first-page":"2181","DOI":"10.1200\/JCO.2009.26.2543","article-title":"Meta-analysis of concomitant versus sequential radiochemotherapy in locally advanced non-small-cell lung cancer","volume":"28","author":"Aup\u00e9rin","year":"2010","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.lungcan.2026.109411_b0265","unstructured":"Osimertinib after Chemoradiotherapy in Stage III EGFR-Mutated NSCLC | New England Journal of Medicine [Internet]. [cited 2025 Nov 6]. Available from: https:\/\/www.nejm.org\/doi\/full\/10.1056\/NEJMoa2402614."},{"key":"10.1016\/j.lungcan.2026.109411_b0270","unstructured":"Research C for DE and. FDA approves osimertinib for locally advanced, unresectable (stage III) non-small cell lung cancer following chemoradiation therapy. FDA [Internet]. 2024 Sep 25 [cited 2025 Nov 7]. Available from: https:\/\/www.fda.gov\/drugs\/resources-information-approved-drugs\/fda-approves-osimertinib-locally-advanced-unresectable-stage-iii-non-small-cell-lung-cancer."},{"key":"10.1016\/j.lungcan.2026.109411_b0275","unstructured":"Tagrisso approved in the EU for patients with unresectable EGFR-mutated lung cancer [Internet]. 2024 [cited 2025 Nov 7]. Available from: https:\/\/www.astrazeneca.com\/content\/astraz\/media-centre\/press-releases\/2024\/tagrisso-approved-in-eu-based-on-laura-trial.html."},{"issue":"1","key":"10.1016\/j.lungcan.2026.109411_b0280","doi-asserted-by":"crossref","first-page":"104","DOI":"10.1016\/S1470-2045(21)00606-9","article-title":"Postoperative radiotherapy versus no postoperative radiotherapy in patients with completely resected non-small-cell lung cancer and proven mediastinal N2 involvement (lung ART): an open-label, randomised, phase 3 trial","volume":"23","author":"Le Pechoux","year":"2022","journal-title":"Lancet Oncol."},{"issue":"3","key":"10.1016\/j.lungcan.2026.109411_b0285","doi-asserted-by":"crossref","DOI":"10.1016\/j.jtho.2025.11.006","article-title":"Radiotherapy for Unresectable locally Advanced NSCLC: a Practical Multidisciplinary Approach to Challenging Scenarios from the International Association for the Study of Lung Cancer Advanced Radiation Technology Subcommittee","volume":"21","author":"Zhu","year":"2026","journal-title":"J. Thorac. Oncol."},{"key":"10.1016\/j.lungcan.2026.109411_b0290","unstructured":"Stephen V Liu: Impressive Results from MDT-BRIDGE at ESMO25 from Dr. Martin Reck - OncoDaily [Internet]. 2025 Oct 18 [cited 2025 Nov 6]. Available from: https:\/\/oncodaily.com\/voices\/mdt-bridge-393300."},{"key":"10.1016\/j.lungcan.2026.109411_b0295","doi-asserted-by":"crossref","DOI":"10.1016\/j.lungcan.2024.108061","article-title":"An international and multidisciplinary EORTC survey on resectability of stage III non-small cell lung cancer","volume":"199","author":"Houda","year":"2025","journal-title":"Lung Cancer"},{"issue":"2","key":"10.1016\/j.lungcan.2026.109411_b0300","doi-asserted-by":"crossref","DOI":"10.1111\/1759-7714.15514","article-title":"Partial Stereotactic Ablative Radiotherapy boost before conventional Radiotherapy (P-SABR) for Large (>\u20095\u2009cm) Unresectable Stage III Nonsmall Cell Lung Cancer","volume":"16","author":"Bai","year":"2025","journal-title":"Thorac Cancer."},{"key":"10.1016\/j.lungcan.2026.109411_b0305","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1016\/j.ctro.2020.09.006","article-title":"CONCORDE: a phase I platform study of novel agents in combination with conventional radiotherapy in non-small-cell lung cancer","volume":"25","author":"Walls","year":"2020","journal-title":"Clinical and Translational Radiation Oncology."},{"issue":"1","key":"10.1016\/j.lungcan.2026.109411_b0310","article-title":"Is a Clinical Target volume (CTV) Necessary in the Treatment of Lung Cancer in the Modern Era Combining 4-D Imaging and Image-guided Radiotherapy (IGRT)?","volume":"8","author":"Kilburn","year":"2016","journal-title":"Cureus"}],"container-title":["Lung Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0169500226004721?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0169500226004721?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,6,28]],"date-time":"2026-06-28T16:21:54Z","timestamp":1782663714000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0169500226004721"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,6]]},"references-count":62,"alternative-id":["S0169500226004721"],"URL":"https:\/\/doi.org\/10.1016\/j.lungcan.2026.109411","relation":{},"ISSN":["0169-5002"],"issn-type":[{"value":"0169-5002","type":"print"}],"subject":[],"published":{"date-parts":[[2026,6]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Navigating controversies in stage III NSCLC: a multidisciplinary case discussion on evolving treatment paradigms","name":"articletitle","label":"Article Title"},{"value":"Lung Cancer","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.lungcan.2026.109411","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 The Authors. Published by Elsevier B.V.","name":"copyright","label":"Copyright"}],"article-number":"109411"}}